ArcticZymes Technologies announced its participation as an associated partner in the CAARE (Consortium for Advanced Analytical and Recovery Engineering) project, alongside an expansion of its ongoing research collaboration with the Austrian Centre of Industrial Biotechnology (acib), supported by additional funding through the COMET program.
Together, these developments reinforce ArcticZymes’ commitment to advancing downstream processing solutions for bionanoparticles, including viral vectors used in gene therapy, vaccines, and oncology applications. Demand for viral vector manufacturing solutions continues to increase, driven by growth in gene therapy and next-generation cell therapy platforms.
The collaboration with acib has already demonstrated that chromatin, rather than freely accessible DNA, represents a key bottleneck in the purification of bionanoparticles. Building on these findings, the extended partnership will further develop enzymatic strategies for chromatin degradation and improved analytical methods for its detection and quantification.
With newly allocated COMET funding of EUR 160,000, matched to ArcticZymes’ contribution, the project gains increased resources to accelerate research activities and deepen experimental work. This includes continued access to acib’s laboratory infrastructure and expertise in bioprocess development.
As the originator of salt-active nucleases, ArcticZymes contributes unique capabilities in enabling DNA and chromatin degradation underprocess-relevant conditions, including high-salt and complex biological matrices. This supports earlier impurity removal, reduces process complexity, and improves the efficiency and consistency of downstream purification.
Participation in the CAARE consortium further extends this work into a broader collaborative framework focused on developing intensified downstream processes to eliminate impurities and improve viral titres. The combined efforts across CAARE and the acib collaboration create strong synergies between fundamental research, process development, and industrial application.
“Expanding our collaboration with acib while joining the CAARE consortium allows us to connect deep scientific insight with broader process innovation initiatives,” said Michael B. Akoh, CEO of ArcticZymes Technologies. “Together, these efforts allow us to develop new solutions and products, addressing key challenges in viral vector manufacturing, directly supporting our customers to develop the next generation of advanced therapies.”
Through these combined initiatives, ArcticZymes continues to contribute to the development of robust, scalable, and efficient downstream processing solutions and future products for next-generation biomanufacturing. These developments will further strengthen ArcticZymes’ position in the expanding advanced therapy market.
To find out more about this exciting initiative, register to attend our upcoming webinar, presenting new data from our collaborators at acib, giving further insights into the challenges of host cell DNA removal in viral vector manufacturing. Click here to book your space.
